{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:44:47Z","timestamp":1794271487170,"version":"4.9.0"},"reference-count":240,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82502222"],"award-info":[{"award-number":["82502222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the fellowship of China National Postdoctoral Program for Innovative Talents","award":["BX20250198"],"award-info":[{"award-number":["BX20250198"]}]},{"name":"the Key R&D Program of Zhejiang","award":["2024SSYS0024, 2024SSYS0023, 2024SSYS0025"],"award-info":[{"award-number":["2024SSYS0024, 2024SSYS0023, 2024SSYS0025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01805-7","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:06:27Z","timestamp":1778249187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases"],"prefix":"10.1186","volume":"19","author":[{"given":"Hongjia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueju","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"1805_CR1","doi-asserted-by":"crossref","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: What Is Next? Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030663"},{"key":"1805_CR2","doi-asserted-by":"publisher","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13:925985.","journal-title":"Front Immunol"},{"issue":"7971","key":"1805_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"1","key":"1805_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127\u201347.","journal-title":"Immunol Rev"},{"issue":"3","key":"1805_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1805_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","volume":"40","author":"P Dabas","year":"2023","unstructured":"Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. Med Oncol. 2023;40(9):275.","journal-title":"Med Oncol"},{"issue":"24","key":"1805_CR7","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1805_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: The evolution of CAR-T cell therapy. Mol Ther. 2025;33(5):2123\u201340.","journal-title":"Mol Ther"},{"issue":"1","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1186\/s12885-024-12651-6","volume":"24","author":"E Montagna","year":"2024","unstructured":"Montagna E, de Campos NSP, Porto VA, da Silva GCP, Suarez ER. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient\u2019s age, and tumor types. BMC Cancer. 2024;24(1):1037.","journal-title":"BMC Cancer"},{"issue":"4","key":"1805_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"4","key":"1805_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","volume":"26","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Han X, Rohrs JA, Bryson P, Liu Y, Li QJ, Zhu B, Wang P. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Mol Ther. 2018;26(4):976\u201385.","journal-title":"Mol Ther"},{"issue":"48","key":"1805_CR12","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1805_CR13","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep. 2018;23(7):2130\u201341.","journal-title":"Cell Rep"},{"issue":"4","key":"1805_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1805_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1805_CR16","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"issue":"3","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imm.13888","volume":"174","author":"S Zhu","year":"2025","unstructured":"Zhu S, Hu J, Lin J, Wang C, Wang E. Co-Expression of Dominant-Negative TGF-\u03b2 Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1\/DAP12-BB-Based CAR-T Cells in Solid Tumours. Immunology. 2025;174(3):310\u201321.","journal-title":"Immunology"},{"issue":"5","key":"1805_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"1805_CR19","first-page":"1976","volume":"44","author":"J Min","year":"2024","unstructured":"Min J, Peng S, Du N, An R, Zhen X, Cao J, Zhou C, Li Z. [Enhanced tumoricidal activity of PD-1 antibody-secreting c-Met CAR-T cells against pancreatic cancer cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2024;44(10):1976\u201384.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"1","key":"1805_CR20","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","volume":"15","author":"S Zuo","year":"2024","unstructured":"Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, Ling Z, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Zong J, Tian Z, Shan L, Tang K, Huang H, Song Y, Niu Q, Zhou D, Feng S, Han Z, Wang G, Wu T, Pan J, Feng X. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun. 2024;15(1):6155.","journal-title":"Nat Commun"},{"key":"1805_CR21","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1805_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"1805_CR23","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"},{"issue":"6","key":"1805_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, B\u00f6ltz S, Manger B, Mackensen A, Schett G. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"1805_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","volume":"18","author":"J Xin Yu","year":"2019","unstructured":"Xin Yu J, Hubbard-Lucey VM, Tang J. The global pipeline of cell therapies for cancer. Nat Rev Drug Discov. 2019;18(11):821\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"1805_CR26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"key":"1805_CR27","unstructured":"FDA. Brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic."},{"key":"1805_CR28","unstructured":"FDA. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. FDA. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"1805_CR29","unstructured":"FDA. Idecabtagene vicleucel for multiple myeloma. FDA. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"1805_CR30","unstructured":"FDA. CARVYKTI. FDA. 2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti."},{"key":"1805_CR31","unstructured":"FDA. AUCATZYL. FDA. 2024. https:\/\/web.archive.org\/web\/20241110084905\/https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl."},{"issue":"9","key":"1805_CR32","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M, Buechner J, Pulsipher MA, Myers GD, Stefanski HE, Martin PL, Nemecek E, Peters C, Yanik G, Khaw SL, Davis KL, Krueger J, Balduzzi A, Boissel N, Tiwari R, O\u2019Donovan D, Grupp SA. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1805_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","volume":"27","author":"N Bouchkouj","year":"2022","unstructured":"Bouchkouj N, Zimmerman M, Kasamon YL, Wang C, Dai T, Xu Z, Wang X, Theoret M, Purohit-Sheth T, George B. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma. Oncologist. 2022;27(7):587\u201394.","journal-title":"Oncologist"},{"key":"1805_CR34","doi-asserted-by":"crossref","unstructured":"Ahmed N, Thiruvengadam SK, Hamadani M, Hu Z-H, Grover N, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang M, Kim S, Bye M, Kharfan-Dabaja MA, Sauter C, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan B, Nunes A, Dalton D, Kloos I, Lee D, Xu H, Pasquini MC, Herrera AF. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025;9(20):5382\u201396.","DOI":"10.1182\/bloodadvances.2024015014"},{"issue":"5","key":"1805_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316.","journal-title":"Blood"},{"issue":"11","key":"1805_CR36","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1805_CR37","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","volume":"30","author":"K Natrajan","year":"2024","unstructured":"Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR. FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2024;30(14):2865\u201371.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1805_CR38","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, Ghobadi A, Guerreiro M, Yallop D, Abedi M, Pantin JM, Yared JA, Beitinjaneh AM, Chaganti S, Hodby K, Menne T, Arellano ML, Malladi R, Shah BD, Mountjoy L, O\u2019Dwyer KM, Peggs KS, Lao-Sirieix P, Zhang Y, Brugger W, Braendle E, Pule M, Bishop MR, DeAngelo DJ, Park JH, Jabbour E. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024;391(23):2219\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"1805_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1805_CR40","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1805_CR41","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"key":"1805_CR42","doi-asserted-by":"crossref","unstructured":"Qin H, Yang L, Chukinas JA, Shah NN, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor NA, Tasian SK, Fry TJ. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immuno Ther Cancer. 2021;9(9):e003149.","DOI":"10.1136\/jitc-2021-003149"},{"issue":"23","key":"1805_CR43","doi-asserted-by":"publisher","first-page":"e2414882","DOI":"10.1002\/adma.202414882","volume":"37","author":"D Zhu","year":"2025","unstructured":"Zhu D, Kim WJ, Lee H, Bao X, Kim P. Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting. Adv Mater. 2025;37(23):e2414882.","journal-title":"Adv Mater"},{"issue":"14","key":"1805_CR44","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"issue":"10379","key":"1805_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, R\u00f6sler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schr\u00f6der R, Uder M, Roemer F, Kr\u00f6nke G, Mackensen A, Schett G. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138.","journal-title":"Lancet"},{"issue":"4","key":"1805_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506\u201315.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1805_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1805_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, Urbano-Ispizua \u00c1, Esteve J, Velasco-Hernandez T, Men\u00e9ndez P. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1805_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"MC Vo","year":"2025","unstructured":"Vo MC, Tran VD, Nguyen VT, Ruzimurodov N, Trung DT, Kim SK, Jung SH, Lee JJ. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol Oncol. 2025;18(1):91.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1805_CR50","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","volume":"93","author":"J Zidan","year":"2005","unstructured":"Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93(5):552\u20136.","journal-title":"Br J Cancer"},{"key":"1805_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.canlet.2017.06.024","volume":"403","author":"J Yang","year":"2017","unstructured":"Yang J, Yan J, Liu B. Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 2017;403:224\u201330.","journal-title":"Cancer Lett"},{"issue":"12","key":"1805_CR52","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375.","journal-title":"Cell Mol Immunol"},{"key":"1805_CR53","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol. 2022;13:927153.","journal-title":"Front Immunol"},{"issue":"1","key":"1805_CR54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, Kumar R, Akil ASA, Macha MA, Haris M, Uddin S, Singh M, Bhat AA. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21(1):449.","journal-title":"J Transl Med"},{"issue":"10","key":"1805_CR55","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"key":"1805_CR56","doi-asserted-by":"publisher","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","volume":"12","author":"A Hern\u00e1ndez-L\u00f3pez","year":"2021","unstructured":"Hern\u00e1ndez-L\u00f3pez A, T\u00e9llez-Gonz\u00e1lez MA, Mondrag\u00f3n-Ter\u00e1n P, Meneses-Acosta A. Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Front Pharmacol. 2021;12:720692.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1805_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-025-01262-4","volume":"15","author":"TK Grischke","year":"2025","unstructured":"Grischke TK, Cooperrider JH, Pula A, Sneider A, Yates S, Jakubowiak AJ, Derman BA. Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025;15(1):47.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1805_CR58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Prasad V, Gellad WF. Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncol. 2018;4(7):994\u20136.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1805_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA, Milone MC. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res. 2018;6(1):36\u201346.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1805_CR60","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1805_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"key":"1805_CR62","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.eclinm.2025.103267","volume":"84","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Liu K, Rosen ST, Liu W, Zhu H. Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2025;84:103267.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"1805_CR63","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","volume":"96","author":"FW Vonberg","year":"2025","unstructured":"Vonberg FW, Malik I, O\u2019Reilly M, Hyare H, Carr AS, Roddie C. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. J Neurol Neurosurg Psychiatry. 2025;96(7):665\u201378.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1805_CR64","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis. 2022;14(6):e1576.","journal-title":"WIREs Mech Dis"},{"key":"1805_CR65","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011.","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"1805_CR66","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.neurol.2024.07.005","volume":"180","author":"R Ursu","year":"2024","unstructured":"Ursu R, Belin C, Cuzzubbo S, Carpentier AF. CAR T-cell-associated neurotoxicity: A comprehensive review. Rev Neurol (Paris). 2024;180(9):989\u201394.","journal-title":"Rev Neurol (Paris)"},{"key":"1805_CR67","doi-asserted-by":"crossref","unstructured":"Baig N, Kammakakam I, Falath W, Kammakakam I. Nanomaterials: a review of synthesis methods, properties, recent progress, and challenges, Mater. Adv. 2 (2021) 1821\u20131871. 2021.","DOI":"10.1039\/D0MA00807A"},{"issue":"1","key":"1805_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-025-01692-4","volume":"18","author":"N Liu","year":"2025","unstructured":"Liu N, Wang X, Wang Z, Kan Y, Fang Y, Gao J, Kong X, Wang J. Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. J Hematol Oncol. 2025;18(1):45.","journal-title":"J Hematol Oncol"},{"key":"1805_CR69","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jconrel.2020.10.014","volume":"329","author":"S Karaosmanoglu","year":"2021","unstructured":"Karaosmanoglu S, Zhou M, Shi B, Zhang X, Williams GR, Chen X. Carrier-free nanodrugs for safe and effective cancer treatment. J Control Release. 2021;329:805\u201332.","journal-title":"J Control Release"},{"key":"1805_CR70","doi-asserted-by":"crossref","unstructured":"Xu Y, Dong X, Xu H, Jiao P, Zhao L-X, Su G. Nanomaterial-based drug delivery systems for pain treatment and relief: from the delivery of a single drug to co-delivery of multiple therapeutics. Pharmaceutics. 2023;15(9):2309.","DOI":"10.3390\/pharmaceutics15092309"},{"key":"1805_CR71","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jconrel.2022.09.013","volume":"350","author":"L Song","year":"2022","unstructured":"Song L, Hao Y, Wang C, Han Y, Zhu Y, Feng L, Miao L, Liu Z. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer. J Control Release. 2022;350:922\u201332.","journal-title":"J Control Release"},{"issue":"8","key":"1805_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11095-019-2656-x","volume":"36","author":"M Cao","year":"2019","unstructured":"Cao M, Long M, Chen Q, Lu Y, Luo Q, Zhao Y, Lu A, Ge C, Zhu L, Chen Z. Development of \u03b2-elemene and Cisplatin Co-Loaded Liposomes for Effective Lung Cancer Therapy and Evaluation in Patient-Derived Tumor Xenografts. Pharm Res. 2019;36(8):121.","journal-title":"Pharm Res"},{"key":"1805_CR73","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jconrel.2023.07.006","volume":"360","author":"D Xia","year":"2023","unstructured":"Xia D, Zhang X, Hao H, Jiang W, Chen C, Li H, Feng L, Li J, Wu Y, Zhang L, Hu Y. Strategies to prolong drug retention in solid tumors by aggregating Endo-CMC nanoparticles. J Control Release. 2023;360:705\u201317.","journal-title":"J Control Release"},{"key":"1805_CR74","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: are we there yet? Int J Mol Sci. 2021;22(1):385.","DOI":"10.3390\/ijms22010385"},{"issue":"7","key":"1805_CR75","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-025-02194-w","volume":"85","author":"L Pagano","year":"2025","unstructured":"Pagano L, Danesi R, Benedetti E, Morgagni R, Romani L, Venditti A. The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety. Drugs. 2025;85(7):855\u201366.","journal-title":"Drugs"},{"issue":"1","key":"1805_CR76","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","volume":"15","author":"JE Cortes","year":"2022","unstructured":"Cortes JE, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. Efficacy and safety of CPX-351 versus 7\u2009+\u20093 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022;15(1):155.","journal-title":"J Hematol Oncol"},{"key":"1805_CR77","doi-asserted-by":"publisher","first-page":"1271722","DOI":"10.3389\/fonc.2023.1271722","volume":"13","author":"C Andrews","year":"2023","unstructured":"Andrews C, Pullarkat V, Recher C. CPX-351 in FLT3-mutated acute myeloid leukemia. Front Oncol. 2023;13:1271722.","journal-title":"Front Oncol"},{"key":"1805_CR78","doi-asserted-by":"crossref","unstructured":"Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372.","DOI":"10.3390\/molecules27041372"},{"key":"1805_CR79","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"1805_CR80","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020;20(3):1578\u201389.","journal-title":"Nano Lett"},{"key":"1805_CR81","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"P Prazeres","year":"2023","unstructured":"Prazeres P, Ferreira H, Costa PAC, da Silva W, Alves MT, Padilla M, Thatte A, Santos AK, Lobo AO, Sabino A, Del Puerto HL, Mitchell MJ, Guimaraes PPG. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells. Int J Nanomed. 2023;18:5891\u2013904.","journal-title":"Int J Nanomed"},{"key":"1805_CR82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, Sun L, Jia Y, Wang Z, Luo T, Tan J, Fang X, Zhu H, Wang J, Yu L, Yan Z. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307.","journal-title":"J Control Release"},{"key":"1805_CR83","doi-asserted-by":"crossref","unstructured":"Wang M, Liao Q, Bai S, Liu X, Peng Y, Liu P, Lu H, Zhu J-K, Zeng C. Co-delivery of multiple rnas via lipid nanoparticles enables precise gene editing of CAR-T cells. Adv Healthcare Mater. 2026;15(1):e01475.","DOI":"10.1002\/adhm.202501475"},{"issue":"1","key":"1805_CR84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-024-01574-1","volume":"17","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, Fobian SF, Gurrieri E, Amin M, D\u2019Agostino VG, Falahati M, Zalba S, Debets R, Garrido MJ, Saeed M, Seynhaeve ALB, Balcioglu HE, Ten Hagen TLM. Lipid-based nanosystems: the next generation of cancer immune therapy. J Hematol Oncol. 2024;17(1):53.","journal-title":"J Hematol Oncol"},{"key":"1805_CR85","doi-asserted-by":"crossref","unstructured":"Si J-X, Liu Z-C, Gu F, Jin X, Ma Y-Y. Nanoparticle-based delivery systems for targeted therapy in brain tumors: progress, challenges and perspectives (Review). Int J Oncol. 2025;67(4):83.","DOI":"10.3892\/ijo.2025.5789"},{"key":"1805_CR86","doi-asserted-by":"publisher","first-page":"1165576","DOI":"10.3389\/fimmu.2023.1165576","volume":"14","author":"YT Qin","year":"2023","unstructured":"Qin YT, Li YP, He XW, Wang X, Li WY, Zhang YK. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Front Immunol. 2023;14:1165576.","journal-title":"Front Immunol"},{"issue":"8","key":"1805_CR87","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS, Stephan MT. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1805_CR88","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41467-017-00505-8","volume":"8","author":"HF Moffett","year":"2017","unstructured":"Moffett HF, Coon ME, Radtke S, Stephan SB, McKnight L, Lambert A, Stoddard BL, Kiem HP, Stephan MT. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat Commun. 2017;8(1):389.","journal-title":"Nat Commun"},{"issue":"3","key":"1805_CR89","first-page":"624","volume":"5","author":"GB Kim","year":"2020","unstructured":"Kim GB, Aragon-Sanabria V, Randolph L, Jiang H, Reynolds JA, Webb BS, Madhankumar A, Lian X, Connor JR, Yang J, Dong C. High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. Bioact Mater. 2020;5(3):624\u201335.","journal-title":"Bioact Mater"},{"issue":"14","key":"1805_CR90","doi-asserted-by":"publisher","first-page":"eabn8264","DOI":"10.1126\/sciadv.abn8264","volume":"8","author":"AK Grosskopf","year":"2022","unstructured":"Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, Gale EC, Jons CK, Klich JH, Yan J, Maikawa CL, Correa S, Ou BS, d\u2019Aquino AI, Cochran JR, Chaudhuri O, Mackall CL, Appel EA. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8(14):eabn8264.","journal-title":"Sci Adv"},{"key":"1805_CR91","doi-asserted-by":"publisher","first-page":"107532","DOI":"10.1016\/j.intimp.2021.107532","volume":"95","author":"F Wang","year":"2021","unstructured":"Wang F, Younis M, Luo Y, Zhang L, Yuan L. Iguratimod-encapsulating PLGA-NPs induce human multiple myeloma cell death via reactive oxygen species and Caspase-dependent signalling. Int Immunopharmacol. 2021;95:107532.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1805_CR92","doi-asserted-by":"publisher","first-page":"nwab172","DOI":"10.1093\/nsr\/nwab172","volume":"9","author":"H Li","year":"2022","unstructured":"Li H, Wang Z, Ogunnaike EA, Wu Q, Chen G, Hu Q, Ci T, Chen Z, Wang J, Wen D, Du H, Jiang J, Sun J, Zhang X, Dotti G, Gu Z. Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy. Natl Sci Rev. 2022;9(3):nwab172.","journal-title":"Natl Sci Rev"},{"issue":"10","key":"1805_CR93","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1039\/D1BM01982A","volume":"10","author":"B Shi","year":"2022","unstructured":"Shi B, Li D, Yao W, Wang W, Jiang J, Wang R, Yan F, Liu H, Zhang H, Ye J. Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin\u2019s lymphoma. Biomater Sci. 2022;10(10):2577\u201389.","journal-title":"Biomater Sci"},{"issue":"11","key":"1805_CR94","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller IC, Zamat A, Sun LK, Phuengkham H, Harris AM, Gamboa L, Yang J, Murad JP, Priceman SJ, Kwong GA. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat Biomed Eng. 2021;5(11):1348\u201359.","journal-title":"Nat Biomed Eng"},{"issue":"43","key":"1805_CR95","doi-asserted-by":"publisher","first-page":"e2102624","DOI":"10.1002\/smll.202102624","volume":"17","author":"L Zhu","year":"2021","unstructured":"Zhu L, Liu J, Zhou G, Liu TM, Dai Y, Nie G, Zhao Q. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. Small. 2021;17(43):e2102624.","journal-title":"Small"},{"issue":"5","key":"1805_CR96","doi-asserted-by":"publisher","first-page":"e2304848","DOI":"10.1002\/smll.202304848","volume":"20","author":"B Rezaei","year":"2024","unstructured":"Rezaei B, Yari P, Sanders SM, Wang H, Chugh VK, Liang S, Mostufa S, Xu K, Wang JP, G\u00f3mez-Pastora J, Wu K. Magnetic Nanoparticles: A Review on Synthesis, Characterization, Functionalization, and Biomedical Applications. Small. 2024;20(5):e2304848.","journal-title":"Small"},{"issue":"2","key":"1805_CR97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17425247.2023.2166484","volume":"20","author":"S Khizar","year":"2023","unstructured":"Khizar S, Elkalla E, Zine N, Jaffrezic-Renault N, Errachid A, Elaissari A. Magnetic nanoparticles: multifunctional tool for cancer therapy. Expert Opin Drug Deliv. 2023;20(2):189\u2013204.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1805_CR98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jcyt.2020.10.006","volume":"23","author":"T Xie","year":"2021","unstructured":"Xie T, Chen X, Fang J, Xue W, Zhang J, Tong H, Liu H, Guo Y, Yang Y, Zhang W. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging. Cytotherapy. 2021;23(3):211\u201322.","journal-title":"Cytotherapy"},{"key":"1805_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.actbio.2020.04.015","volume":"109","author":"W Nawaz","year":"2020","unstructured":"Nawaz W, Xu S, Li Y, Huang B, Wu X, Wu Z. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy. Acta Biomater. 2020;109:21\u201336.","journal-title":"Acta Biomater"},{"issue":"1","key":"1805_CR100","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16(1):25\u201336.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1805_CR101","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-024-00525-3","volume":"13","author":"J Xu","year":"2024","unstructured":"Xu J, Liu W, Fan F, Zhang B, Sun C, Hu Y. Advances in nano-immunotherapy for hematological malignancies. Exp Hematol Oncol. 2024;13(1):57.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"1805_CR102","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/imm.13642","volume":"169","author":"X Yin","year":"2023","unstructured":"Yin X, He L, Guo Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. Immunology. 2023;169(4):400\u201311.","journal-title":"Immunology"},{"issue":"9","key":"1805_CR103","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41565-025-02008-w","volume":"20","author":"N Lafuente-G\u00f3mez","year":"2025","unstructured":"Lafuente-G\u00f3mez N, Kang S, Mooney DJ. Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies. Nat Nanotechnol. 2025;20(9):1186\u201398.","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"1805_CR104","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang L, Zheng Y, Melo MB, Mabardi L, Casta\u00f1o AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707\u201316.","journal-title":"Nat Biotechnol"},{"key":"1805_CR105","doi-asserted-by":"publisher","first-page":"121341","DOI":"10.1016\/j.biomaterials.2021.121341","volume":"281","author":"Y Luo","year":"2022","unstructured":"Luo Y, Chen Z, Sun M, Li B, Pan F, Ma A, Liao J, Yin T, Tang X, Huang G, Zhang B, Pan H, Zheng M, Cai L. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341.","journal-title":"Biomaterials"},{"issue":"1","key":"1805_CR106","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","volume":"14","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1805_CR107","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41565-022-01261-7","volume":"18","author":"C Shi","year":"2023","unstructured":"Shi C, Zhang Q, Yao Y, Zeng F, Du C, Nijiati S, Wen X, Zhang X, Yang H, Chen H, Guo Z, Zhang X, Gao J, Guo W, Chen X, Zhou Z. Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics. Nat Nanotechnol. 2023;18(1):86\u201397.","journal-title":"Nat Nanotechnol"},{"key":"1805_CR108","doi-asserted-by":"crossref","unstructured":"Liu H, Liu X, Zhou X, Duan S, Huang X, Fei H, Kou Y. Application of nanobody-based CAR-T in tumor immunotherapy (Review). Int J Mol Med. 2025;56(5):187.","DOI":"10.3892\/ijmm.2025.5628"},{"issue":"9","key":"1805_CR109","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","volume":"411","author":"JP Salvador","year":"2019","unstructured":"Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019;411(9):1703\u201313.","journal-title":"Anal Bioanal Chem"},{"issue":"7","key":"1805_CR110","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, Cai H, Dai Z, Jin J, Yang Y, Hu G, Mao X, Zhou J, Zhu L, Huang L. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(7):2331\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"1805_CR111","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, Wang H, Chen J, Liu H, Xiong M, Liu Y, Wang L. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2025;145(10):1022\u201333.","journal-title":"Blood"},{"issue":"8","key":"1805_CR112","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-22-1491","volume":"29","author":"JD Clubb","year":"2023","unstructured":"Clubb JD, Gao TA, Chen YY. Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes. Clin Cancer Res. 2023;29(8):1390\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1805_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acssynbio.1c00256","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang C, Zhuang Q, Liu J, Liu X. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. ACS Synth Biol. 2022;11(1):1\u201315.","journal-title":"ACS Synth Biol"},{"issue":"9","key":"1805_CR114","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1002\/ctm2.1020","volume":"12","author":"K Huang","year":"2022","unstructured":"Huang K, Liu X, Han G, Zhou Y. Nano-optogenetic immunotherapy. Clin Transl Med. 2022;12(9):e1020.","journal-title":"Clin Transl Med"},{"issue":"12","key":"1805_CR115","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen NT, Huang K, Zeng H, Jing J, Wang R, Fang S, Chen J, Liu X, Huang Z, You MJ, Rao A, Huang Y, Han G, Zhou Y. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424\u201334.","journal-title":"Nat Nanotechnol"},{"key":"1805_CR116","doi-asserted-by":"crossref","unstructured":"Wang S, Li W, Li J, Guo Z, Chen J, Hu Z. Antigen escape in CAR-T therapy: a tumor microenvironment perspective from hematological to solid tumors. Int J Cancer. 2026;158(4):835\u201346.","DOI":"10.1002\/ijc.70117"},{"issue":"1","key":"1805_CR117","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, Chen W, Yan Z, Sang W, Qi K, Li D, Zhu F, Li Z, Qiao J, Wu Q, Zeng L, Fei X, Gu W, Miao Y, Xu K, Zheng J, Cao J. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15(1):3371.","journal-title":"Nat Commun"},{"issue":"1","key":"1805_CR118","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD. Jr., Zhan F. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15(1):615.","journal-title":"Nat Commun"},{"issue":"2","key":"1805_CR119","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","volume":"30","author":"SR Zanetti","year":"2022","unstructured":"Zanetti SR, Velasco-Hernandez T, Gutierrez-Ag\u00fcera F, D\u00edaz VM, Romec\u00edn PA, Roca-Ho H, S\u00e1nchez-Mart\u00ednez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Men\u00e9ndez P. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Mol Ther. 2022;30(2):550\u201363.","journal-title":"Mol Ther"},{"issue":"9","key":"1805_CR120","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, Wang X, Xu H, Cui J, Wu W, Zhao K, Nagler A, Chang AH, Hu Y, Huang H. CD19\/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed\/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunol Res. 2021;9(9):1061\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1805_CR121","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1805_CR122","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropuli\u0107 B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569\u201375.","journal-title":"Nat Med"},{"issue":"14","key":"1805_CR123","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood"},{"key":"1805_CR124","doi-asserted-by":"crossref","unstructured":"De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B. Nanobody based dual specific CARs. Int J Mol Sci. 2018;19(2):403.","DOI":"10.3390\/ijms19020403"},{"key":"1805_CR125","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.omto.2023.07.007","volume":"30","author":"B Xia","year":"2023","unstructured":"Xia B, Lin K, Wang X, Chen F, Zhou M, Li Y, Lin Y, Qiao Y, Li R, Zhang W, He X, Zou F, Li L, Lu L, Chen C, Li W, Zhang H, Liu B. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics. 2023;30:86\u2013102.","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"1805_CR126","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"issue":"1","key":"1805_CR127","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, Al-Gazally ME, Alsaikhan F, Rizaev JA, Mohammad TAM, Tahmasebi S. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1805_CR128","first-page":"20","volume":"10","author":"GL Ma","year":"2023","unstructured":"Ma GL, Lin WF. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Mil Med Res. 2023;10(1):20.","journal-title":"Mil Med Res"},{"issue":"9","key":"1805_CR129","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, Such GK. Polymeric Nanoparticles for Drug Delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"issue":"3","key":"1805_CR130","doi-asserted-by":"publisher","first-page":"243","DOI":"10.7150\/ntno.65544","volume":"6","author":"CK Lee","year":"2022","unstructured":"Lee CK, Atibalentja DF, Yao LE, Park J, Kuruvilla S, Felsher DW. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. Nanotheranostics. 2022;6(3):243\u201355.","journal-title":"Nanotheranostics"},{"issue":"3","key":"1805_CR131","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","volume":"185","author":"G Morad","year":"2022","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022;185(3):576.","journal-title":"Cell"},{"issue":"1","key":"1805_CR132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41551-019-0503-3","volume":"4","author":"NJ Shah","year":"2020","unstructured":"Shah NJ, Najibi AJ, Shih TY, Mao AS, Sharda A, Scadden DT, Mooney DJ. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat Biomed Eng. 2020;4(1):40\u201351.","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"1805_CR133","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","volume":"5","author":"X Xie","year":"2021","unstructured":"Xie X, Hu Y, Ye T, Chen Y, Zhou L, Li F, Xi X, Wang S, He Y, Gao X, Wei W, Ma G, Li Y. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2021;5(5):414\u201328.","journal-title":"Nat Biomed Eng"},{"issue":"23","key":"1805_CR134","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1007\/s00018-013-1339-8","volume":"70","author":"E Peranzoni","year":"2013","unstructured":"Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E. Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci. 2013;70(23):4431\u201348.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1805_CR135","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhu Y, Mei J, Liu Y, Zhou G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18(1):65.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1805_CR136","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","volume":"9","author":"MB Schaaf","year":"2018","unstructured":"Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115.","journal-title":"Cell Death Dis"},{"issue":"23","key":"1805_CR137","doi-asserted-by":"publisher","first-page":"e1900192","DOI":"10.1002\/adma.201900192","volume":"31","author":"Q Chen","year":"2019","unstructured":"Chen Q, Hu Q, Dukhovlinova E, Chen G, Ahn S, Wang C, Ogunnaike EA, Ligler FS, Dotti G, Gu Z. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells. Adv Mater. 2019;31(23):e1900192.","journal-title":"Adv Mater"},{"issue":"8","key":"1805_CR138","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1021\/acsnano.7b06301","volume":"12","author":"S Stapleton","year":"2018","unstructured":"Stapleton S, Dunne M, Milosevic M, Tran CW, Gold MJ, Vedadi A, McKee TD, Ohashi PS, Allen C, Jaffray DA. Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics. ACS Nano. 2018;12(8):7583\u2013600.","journal-title":"ACS Nano"},{"issue":"14","key":"1805_CR139","doi-asserted-by":"publisher","first-page":"e2007494","DOI":"10.1002\/smll.202007494","volume":"17","author":"Z Chen","year":"2021","unstructured":"Chen Z, Pan H, Luo Y, Yin T, Zhang B, Liao J, Wang M, Tang X, Huang G, Deng G, Zheng M, Cai L. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy. Small. 2021;17(14):e2007494.","journal-title":"Small"},{"issue":"2","key":"1805_CR140","doi-asserted-by":"publisher","first-page":"e2407425","DOI":"10.1002\/adma.202407425","volume":"37","author":"Q Zou","year":"2025","unstructured":"Zou Q, Liao K, Li G, Huang X, Zheng Y, Yang G, Luo M, Xue EY, Lan C, Wang S, Shen Y, Luo D, Ng DKP, Liu Q. Photo-metallo-immunotherapy: Fabricating Chromium-Based Nanocomposites to Enhance CAR-T Cell Infiltration and Cytotoxicity against Solid Tumors. Adv Mater. 2025;37(2):e2407425.","journal-title":"Adv Mater"},{"key":"1805_CR141","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijbiomac.2021.09.037","volume":"190","author":"Y Dong","year":"2021","unstructured":"Dong Y, Li S, Li X, Wang X. Smart MXene\/agarose hydrogel with photothermal property for controlled drug release. Int J Biol Macromol. 2021;190:693\u20139.","journal-title":"Int J Biol Macromol"},{"key":"1805_CR142","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jcis.2021.07.004","volume":"604","author":"H Cao","year":"2021","unstructured":"Cao H, Jiang B, Yang Y, Zhao M, Sun N, Xia J, Gao X, Li J. Cell membrane covered polydopamine nanoparticles with two-photon absorption for precise photothermal therapy of cancer. J Colloid Interface Sci. 2021;604:596\u2013603.","journal-title":"J Colloid Interface Sci"},{"issue":"3","key":"1805_CR143","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.7150\/thno.40291","volume":"10","author":"W Ma","year":"2020","unstructured":"Ma W, Zhu D, Li J, Chen X, Xie W, Jiang X, Wu L, Wang G, Xiao Y, Liu Z, Wang F, Li A, Shao D, Dong W, Liu W, Yuan Y. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281\u201395.","journal-title":"Theranostics"},{"issue":"88","key":"1805_CR144","doi-asserted-by":"publisher","first-page":"20130527","DOI":"10.1098\/rsif.2013.0527","volume":"10","author":"M Rybinski","year":"2013","unstructured":"Rybinski M, Szymanska Z, Lasota S, Gambin A. Modelling the efficacy of hyperthermia treatment. J R Soc Interface. 2013;10(88):20130527.","journal-title":"J R Soc Interface"},{"issue":"Pt 1","key":"1805_CR145","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2021.07.014","volume":"86","author":"M Regimbeau","year":"2022","unstructured":"Regimbeau M, Abrey J, Vautrot V, Causse S, Gobbo J, Garrido C. Heat shock proteins and exosomes in cancer theranostics. Semin Cancer Biol. 2022;86(Pt 1):46\u201357.","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"1805_CR146","doi-asserted-by":"publisher","first-page":"14443","DOI":"10.1039\/D3RA02620E","volume":"13","author":"S Duan","year":"2023","unstructured":"Duan S, Hu Y, Zhao Y, Tang K, Zhang Z, Liu Z, Wang Y, Guo H, Miao Y, Du H, Yang D, Li S, Zhang J. Nanomaterials for photothermal cancer therapy. RSC Adv. 2023;13(21):14443\u201360.","journal-title":"RSC Adv"},{"issue":"8","key":"1805_CR147","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41565-025-01924-1","volume":"20","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li Q, Qu C, Jiang Z, Jia G, Lan G, Luan Y. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer. Nat Nanotechnol. 2025;20(8):1131\u201341.","journal-title":"Nat Nanotechnol"},{"issue":"11 Suppl","key":"1805_CR148","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.cgh.2009.07.039","volume":"7","author":"S Pandol","year":"2009","unstructured":"Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S44\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"39","key":"1805_CR149","doi-asserted-by":"publisher","first-page":"19609","DOI":"10.1073\/pnas.1908626116","volume":"116","author":"C Tian","year":"2019","unstructured":"Tian C, Clauser KR, \u00d6hlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A. 2019;116(39):19609\u201318.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1805_CR150","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, Izadi S, Hassanzadeh A, Shirafkan N, Tahmasebi S, Khiavi FM. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"1805_CR151","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12032-025-02818-x","volume":"42","author":"A Sinha","year":"2025","unstructured":"Sinha A, Ghosh D, Karati D. Tumor microenvironment and immunotherapy: from bench to bedside. Med Oncol. 2025;42(7):244.","journal-title":"Med Oncol"},{"issue":"7","key":"1805_CR152","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41401-020-0400-z","volume":"41","author":"J Gao","year":"2020","unstructured":"Gao J, Wang WQ, Pei Q, Lord MS, Yu HJ. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):986\u201394.","journal-title":"Acta Pharmacol Sin"},{"issue":"13","key":"1805_CR153","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","volume":"78","author":"F Zhang","year":"2018","unstructured":"Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, Stephan MT. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. Cancer Res. 2018;78(13):3718\u201330.","journal-title":"Cancer Res"},{"issue":"1","key":"1805_CR154","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G, Huang X. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262.","journal-title":"Nat Commun"},{"issue":"3","key":"1805_CR155","doi-asserted-by":"publisher","first-page":"e1395997","DOI":"10.1080\/2162402X.2017.1395997","volume":"7","author":"EK Moon","year":"2018","unstructured":"Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology. 2018;7(3):e1395997.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1805_CR156","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1039\/C9RA09021E","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Jin Y, Cui H, Yan X, Fan K. Nanozyme-based catalytic theranostics. RSC Adv. 2019;10(1):10\u201320.","journal-title":"RSC Adv"},{"issue":"1","key":"1805_CR157","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"1","key":"1805_CR158","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12967-025-06636-7","volume":"23","author":"Y Xu","year":"2025","unstructured":"Xu Y, Liao J, Wang J, Gao Y, Wu Y, Gao M, Liu W, Zhang D, Zhang W, Huang A. Bidirectional roles of nanoenzymes in enhancing GPC3-CAR T cell infiltration and cancer immunotherapy. J Transl Med. 2025;23(1):653.","journal-title":"J Transl Med"},{"issue":"7","key":"1805_CR159","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, Kim YJ, Siegler E, Chen X, Rohrs JA, Liu Y, Wang P. CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction. Cancer Immunol Res. 2018;6(7):812\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1805_CR160","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4049\/jimmunol.174.2.1073","volume":"174","author":"CM Lappas","year":"2005","unstructured":"Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4\u2009+\u2009T cells. J Immunol. 2005;174(2):1073\u201380.","journal-title":"J Immunol"},{"issue":"51","key":"1805_CR161","doi-asserted-by":"publisher","first-page":"56712","DOI":"10.1021\/acsami.0c15239","volume":"12","author":"Z Luo","year":"2020","unstructured":"Luo Z, Liu Z, Liang Z, Pan J, Xu J, Dong J, Bai Y, Deng H, Wei S. Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors. ACS Appl Mater Interfaces. 2020;12(51):56712\u201322.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"23\u201324","key":"1805_CR162","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1089\/ten.tea.2016.0064","volume":"22","author":"A Rodriguez-Brotons","year":"2016","unstructured":"Rodriguez-Brotons A, Bietiger W, Peronet C, Langlois A, Magisson J, Mura C, Sookhareea C, Polard V, Jeandidier N, Zal F, Pinget M, Sigrist S, Maillard E. Comparison of Perfluorodecalin and HEMOXCell as Oxygen Carriers for Islet Oxygenation in an In Vitro Model of Encapsulation. Tissue Eng Part A. 2016;22(23\u201324):1327\u201336.","journal-title":"Tissue Eng Part A"},{"key":"1805_CR163","doi-asserted-by":"publisher","first-page":"684642","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell M, Gottschalk S. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front Immunol. 2021;12:684642.","journal-title":"Front Immunol"},{"key":"1805_CR164","doi-asserted-by":"crossref","unstructured":"Xie B, Li Z, Zhou J, Wang W. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers. 2022;14(13):3230.","DOI":"10.3390\/cancers14133230"},{"issue":"8Supplement1","key":"1805_CR165","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1538-7445.AM2025-4799","volume":"85","author":"J Li","year":"2025","unstructured":"Li J, Sun Y, Xia Y, Lou J, Guo J, Rong L, Sun D, Lin Z, Liu Y, Wang X, Xu W, Qian Q. Abstract 4799: MSLN and MUC1 dual-targeting CAR-T with conditional activation and tumor specificity to improve clinical safety and efficacy. Cancer Res. 2025;85(8Supplement1):4799\u20134799.","journal-title":"Cancer Res"},{"issue":"2","key":"1805_CR166","doi-asserted-by":"publisher","first-page":"227","DOI":"10.59249\/GVNM8843","volume":"98","author":"U Ahmad","year":"2025","unstructured":"Ahmad U, Islam A, Khan MM, Akhtar J. Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators. Yale J Biol Med. 2025;98(2):227\u201335.","journal-title":"Yale J Biol Med"},{"key":"1805_CR167","doi-asserted-by":"crossref","unstructured":"G\u00fclow K, T\u00fcmen D, Heumann P, Schmid S, Kandulski A, M\u00fcller M, Kunst C. Unraveling the role of reactive oxygen species in T lymphocyte signaling. Int J Mol Sci. 2024;25(11):6114.","DOI":"10.3390\/ijms25116114"},{"issue":"20","key":"1805_CR168","doi-asserted-by":"publisher","first-page":"e2304615","DOI":"10.1002\/adhm.202304615","volume":"13","author":"J Long","year":"2024","unstructured":"Long J, Wang Y, Jiang X, Ge J, Chen M, Zheng B, Wang R, Wang M, Xu M, Ke Q, Wang J. Nanomaterials Boost CAR-T Therapy for Solid Tumors. Adv Healthc Mater. 2024;13(20):e2304615.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"1805_CR169","doi-asserted-by":"publisher","first-page":"11238","DOI":"10.1021\/acsnano.0c03109","volume":"14","author":"AE Barberio","year":"2020","unstructured":"Barberio AE, Smith SG, Correa S, Nguyen C, Nhan B, Melo M, Tokatlian T, Suh H, Irvine DJ, Hammond PT. Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery. ACS Nano. 2020;14(9):11238\u201353.","journal-title":"ACS Nano"},{"issue":"25","key":"1805_CR170","doi-asserted-by":"publisher","first-page":"e2501645","DOI":"10.1002\/smll.202501645","volume":"21","author":"B Wang","year":"2025","unstructured":"Wang B, Xue Y, Jia Y, Duan Y, Li D, Sui M, Feng Y, Wang L, Ding H, Wang X, Zhang T, Sun Y, Liu H, Qi J, Duan J, Zhao S, Zhu Q. IL-21 Loading CaMnCO(3) Vitality Backpacks Boost CAR-T Cell Synergistic Immunotherapy. Small. 2025;21(25):e2501645.","journal-title":"Small"},{"key":"1805_CR171","doi-asserted-by":"crossref","unstructured":"Hao M, Hou S, Li W, Li K, Xue L, Hu Q, Zhu L, Chen Y, Sun H, Ju C, Zhang C. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Trans Med. 2020;12(571):eaaz6667.","DOI":"10.1126\/scitranslmed.aaz6667"},{"issue":"7596","key":"1805_CR172","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, Meng X, Li L, Wang J, Xu C, Yan C, Wang L, Chang CC, Chang TY, Zhang T, Zhou P, Song BL, Liu W, Sun SC, Liu X, Li BL, Xu C. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651\u20135.","journal-title":"Nature"},{"key":"1805_CR173","doi-asserted-by":"publisher","first-page":"102591","DOI":"10.1016\/j.nano.2022.102591","volume":"45","author":"X Chen","year":"2022","unstructured":"Chen X, Gao M, An S, Zhao L, Han W, Wan W, Chen J, Ma S, Cai W, Cao Y, Ding D, Yang YY, Cheng L, Zheng Y. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine. 2022;45:102591.","journal-title":"Nanomedicine"},{"issue":"4","key":"1805_CR174","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","volume":"16","author":"C Wang","year":"2016","unstructured":"Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Lett. 2016;16(4):2334\u201340.","journal-title":"Nano Lett"},{"issue":"9","key":"1805_CR175","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, Li H, Archibong E, Chen Q, Ruan H, Ahn S, Dukhovlinova E, Kang Y, Wen D, Dotti G, Gu Z. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng. 2021;5(9):1038\u201347.","journal-title":"Nat Biomed Eng"},{"key":"1805_CR176","doi-asserted-by":"publisher","first-page":"121872","DOI":"10.1016\/j.biomaterials.2022.121872","volume":"291","author":"W Zhou","year":"2022","unstructured":"Zhou W, Lei S, Liu M, Li D, Huang Y, Hu X, Yang J, Li J, Fu M, Zhang M, Wang F, Li J, Men K, Wang W. Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. Biomaterials. 2022;291:121872.","journal-title":"Biomaterials"},{"issue":"2","key":"1805_CR177","first-page":"185","volume":"51","author":"B Ye","year":"2022","unstructured":"Ye B, Hu Y, Zhang M, Huang H. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022;51(2):185\u201391.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"1805_CR178","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"key":"1805_CR179","doi-asserted-by":"crossref","unstructured":"Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology. Cells. 2020;9(9):2102.","DOI":"10.3390\/cells9092102"},{"key":"1805_CR180","doi-asserted-by":"publisher","first-page":"1492215","DOI":"10.3389\/fchem.2024.1492215","volume":"12","author":"M Tian","year":"2024","unstructured":"Tian M, Liu X, Pei H. Nanomaterial-based cancer immunotherapy: enhancing treatment strategies. Front Chem. 2024;12:1492215.","journal-title":"Front Chem"},{"issue":"1","key":"1805_CR181","first-page":"101015","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang X, Chang Z, Zhu W, Ma Y, He H. Polymeric nanocarriers for therapeutic gene delivery. Asian J Pharm Sci. 2025;20(1):101015.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"1805_CR182","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","volume":"31","author":"R-M Lu","year":"2024","unstructured":"Lu R-M, Hsu H-E, Perez SJLP, Kumari M, Chen G-H, Hong M-H, Lin Y-S, Liu C-H, Ko S-H, Concio CAP, Su Y-J, Chang Y-H, Li W-S, Wu H-C. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J Biomed Sci. 2024;31(1):89.","journal-title":"J Biomed Sci"},{"issue":"33","key":"1805_CR183","doi-asserted-by":"publisher","first-page":"10085","DOI":"10.1039\/D5TB01556A","volume":"13","author":"Y Sui","year":"2025","unstructured":"Sui Y, Hou X, Zhang J, Hong X, Wang H, Xiao Y, Zeng X. Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy. J Mater Chem B. 2025;13(33):10085\u2013117.","journal-title":"J Mater Chem B"},{"issue":"1","key":"1805_CR184","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/s41467-025-59093-7","volume":"16","author":"J Yan","year":"2025","unstructured":"Yan J, Wang SY, Su Q, Zou MW, Zhou ZY, Shou J, Huo Y. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile. Nat Commun. 2025;16(1):3748.","journal-title":"Nat Commun"},{"issue":"9","key":"1805_CR185","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12032-025-02928-6","volume":"42","author":"YA Albalawi","year":"2025","unstructured":"Albalawi YA. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. Med Oncol. 2025;42(9):378.","journal-title":"Med Oncol"},{"issue":"1","key":"1805_CR186","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080.","journal-title":"Nat Commun"},{"key":"1805_CR187","doi-asserted-by":"publisher","first-page":"102518","DOI":"10.1016\/j.nantod.2024.102518","volume":"59","author":"Y Li","year":"2024","unstructured":"Li Y, Tian Y, Li C, Fang W, Li X, Jing Z, Yang Z, Zhang X, Huang Y, Gong J, Meng F, Qi L, Liang X, Hou L, Lv K, Zhang X. In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells. Nano Today. 2024;59:102518.","journal-title":"Nano Today"},{"issue":"5","key":"1805_CR188","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cell.2013.10.019","volume":"155","author":"D Mu\u00f1oz-Esp\u00edn","year":"2013","unstructured":"Mu\u00f1oz-Esp\u00edn D, Ca\u00f1amero M, Maraver A, G\u00f3mez-L\u00f3pez G, Contreras J, Murillo-Cuesta S, Rodr\u00edguez-Baeza A, Varela-Nieto I, Ruberte J, Collado M, Serrano M. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155(5):1104\u201318.","journal-title":"Cell"},{"issue":"12","key":"1805_CR189","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41580-024-00738-8","volume":"25","author":"V Suryadevara","year":"2024","unstructured":"Suryadevara V, Hudgins AD, Rajesh A, Pappalardo A, Karpova A, Dey AK, Hertzel A, Agudelo A, Rocha A, Soygur B, Schilling B, Carver CM, Aguayo-Mazzucato C, Baker DJ, Bernlohr DA, Jurk D, Mangarova DB, Quardokus EM, Enninga EAL, Schmidt EL, Chen F, Duncan FE, Cambuli F, Kaur G, Kuchel GA, Lee G, Daldrup-Link HE, Martini H, Phatnani H, Al-Naggar IM, Rahman I, Nie J, Passos JF, Silverstein JC, Campisi J, Wang J, Iwasaki K, Barbosa K, Metis K, Nernekli K, Niedernhofer LJ, Ding L, Wang L, Adams LC, Ruiyang L, Doolittle ML, Teneche MG, Schafer MJ, Xu M, Hajipour M, Boroumand M, Basisty N, Sloan N, Slavov N, Kuksenko O, Robson P, Gomez PT, Vasilikos P, Adams PD, Carapeto P, Zhu Q, Ramasamy R, Perez-Lorenzo R, Fan R, Dong R, Montgomery RR, Shaikh S, Vickovic S, Yin S, Kang S, Suvakov S, Khosla S, Garovic VD, Menon V, Xu Y, Song Y, Suh Y, Dou Z, Neretti N. SenNet recommendations for detecting senescent cells in different tissues. Nat Rev Mol Cell Biol. 2024;25(12):1001\u201323.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7814","key":"1805_CR190","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127\u201332.","journal-title":"Nature"},{"issue":"3","key":"1805_CR191","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor C, Fern\u00e1ndez-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL, Jones LW, Sadelain M, Lowe SW. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. 2024;4(3):336\u201349.","journal-title":"Nat Aging"},{"issue":"7","key":"1805_CR192","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Ma B, Li B, Li Z, Gao M, Zhao H, Peng R, Hu J, Wang Y, You W, Gui X, Wang R, Hu X, Chen B, Zhang Y, Hao Y, Sun X, Rao P, Zhang L, Lu M, Zhou D, Yang Y, Deng M, Miao L. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6(7):102209.","journal-title":"Cell Rep Med"},{"issue":"8","key":"1805_CR193","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.xcrm.2025.102250","volume":"6","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lin L, Wang X, Li J, Pan Q, Kou H, Yin J, Gao F, Liao X, Zhang C, Yin Q, Zhao C, Li X, Lin J, Xu Y, Qiu M, Luo D, Qu L. Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell Rep Med. 2025;6(8):102250.","journal-title":"Cell Rep Med"},{"issue":"709","key":"1805_CR194","doi-asserted-by":"publisher","first-page":"eadd1951","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang D, Sun B, Li S, Wei W, Liu X, Cui X, Zhang X, Liu N, Yan L, Deng Y, Zhao X. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med. 2023;15(709):eadd1951.","journal-title":"Sci Transl Med"},{"issue":"11","key":"1805_CR195","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","volume":"21","author":"F Porsch","year":"2024","unstructured":"Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780\u2013807.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1805_CR196","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025;7(6):e434\u201347.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1805_CR197","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137.","journal-title":"J Immunother Cancer"},{"issue":"6382","key":"1805_CR198","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"9","key":"1805_CR199","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, Haghikia A, Merkel PA, Caricchio R, D\u2019Agostino MA, Locatelli F, June CH, Mougiakakos D. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531\u201344.","journal-title":"Nat Rev Rheumatol"},{"key":"1805_CR200","doi-asserted-by":"crossref","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, Xiang N, Wang X, Zha G-F, Schett G, Chen Z. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. New Engl J Med. 2025;393(15):1542\u20134.","DOI":"10.1056\/NEJMc2509522"},{"issue":"6576","key":"1805_CR201","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Pur\u00e9 E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"key":"1805_CR202","doi-asserted-by":"publisher","first-page":"1056400","DOI":"10.3389\/fimmu.2022.1056400","volume":"13","author":"SY Pan","year":"2022","unstructured":"Pan SY, Tian HM, Zhu Y, Gu WJ, Zou H, Wu XQ, Cheng RJ, Yang Z. Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored. Front Immunol. 2022;13:1056400.","journal-title":"Front Immunol"},{"issue":"8","key":"1805_CR203","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Sch\u00e4fer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Kr\u00f6nke G, Mackensen A, Schett G. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"6753","key":"1805_CR204","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, Li JJ, Soldevila F, Chu DSH, Nguyen DP, Yong QC, Ross B, Nguyen M, Vestal J, Roberts S, Galvan D, Vega JB, Jhung D, Butcher M, Nguyen J, Zhang S, Fernandez C, Chen J, Herrera C, Kuo Y, Pica EM, Mondal G, Mammen AL, Scholler J, Tanis SP, Sievers SA, Frantz AM, Adams GB, Shawver L, Farzaneh-Far R, Rosenzweig M, Karmali PP, Bot AI, June CH, Aghajanian H. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"key":"1805_CR205","doi-asserted-by":"crossref","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, Klichinsky M, Neumann F, Shah JV, Swayer AJ, Trudeau K, Weissman D, Stephan MT, Buchholz CJ, June CH. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25(2):116\u201337.","DOI":"10.1038\/s41573-025-01291-5"},{"key":"1805_CR206","doi-asserted-by":"crossref","unstructured":"Zheng Z, Liu Y, Wang G, Li X, Peng S, Jia Z, Yue X, Fu Z, Zhao X, Han M, Yang Z, Tang C, Gao J, Kong Z, Chen C, Zhao K, Li T, Jiang X, Jing W. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33(4):589.e585\u2013604.e585.","DOI":"10.1016\/j.stem.2026.02.006"},{"issue":"10","key":"1805_CR207","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Halladay T, Yang L. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;25(10):725\u201344.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1805_CR208","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/d41573-023-00002-2","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M. The landscape for lipid-nanoparticle-based genomic medicines. Nat Rev Drug Discov. 2023;22(5):349\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1805_CR209","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. In vivo CAR T cells move into clinical trials. Nat Rev Drug Discov. 2024;23(10):727\u201330.","journal-title":"Nat Rev Drug Discov"},{"issue":"10500","key":"1805_CR210","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, Zhang J, Li C, Hu Y, Mei H. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 2025;406(10500):228\u201331.","journal-title":"Lancet"},{"issue":"16suppl","key":"1805_CR211","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2025.43.16_suppl.2591","volume":"43","author":"CR Lemech","year":"2025","unstructured":"Lemech CR, Cosman R, Humphries TG, Kichenadasse G, Richardson GE, Nagrial A, Teng C, Liu J, Joshua AM, Cohen H, Mo J, Harvey K, Zhang H, Ling Z, King N, Barnett M, Cioffi M, Maurer MA, Getts D, Swarbrick A. First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors. J Clin Oncol. 2025;43(16suppl):2591\u20132591.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1805_CR212","first-page":"TPS4218","volume":"43","author":"TG Humphries","year":"2025","unstructured":"Humphries TG, Roberts SK, Sim H-W, Kim YJ, Chon HJ, Heo J, Cohen H, Cioffi M, Barnett M, Maurer MA, Andelkovic V. A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma. J Clin Oncol. 2025;43(16suppl):TPS4218\u20134218.","journal-title":"J Clin Oncol"},{"key":"1805_CR213","unstructured":"Open-label, single-arm, exploratory clinical trial to evaluate the safety, tolerability and efficacy of JCXH-213 in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06618313."},{"key":"1805_CR214","doi-asserted-by":"crossref","unstructured":"Fang J, Ding N, Guo X, Sun Y, Zhang Z, Xie B, Li Z, Wang H, Mao W, Lin Z, Qin F, Yuan M, Chu W, Qin H, Qian Q, Xu Q. \u03b1PD-1-mesoCAR-T cells partially inhibit the growth of advanced\/refractory ovarian cancer in a patient along with daily apatinib. J Immuno Ther Cancer. 2021;9(2):e001162.","DOI":"10.1136\/jitc-2020-001162"},{"issue":"16","key":"1805_CR215","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood.2024024952","volume":"144","author":"H Srinagesh","year":"2024","unstructured":"Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood. 2024;144(16):1689\u201398.","journal-title":"Blood"},{"issue":"18","key":"1805_CR216","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1182\/bloodadvances.2025016322","volume":"9","author":"XG Zhang","year":"2025","unstructured":"Zhang XG, Wang L, Yang J, Hu XN, Wang H, Zhang LN, Zhou X, Liu Y, Wang Q, Lu PH. Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma. Blood Adv. 2025;9(18):4543\u201352.","journal-title":"Blood Adv"},{"key":"1805_CR217","unstructured":"A multicenter, open-label, non-randomized, single-arm clinical study of nanobody CD5-CAR T cell therapy for refractory\/relapsed T lymphocyte malignancies [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07070323."},{"issue":"11","key":"1805_CR218","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, L\u00fcke F, Kutsch N, M\u00fcller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, K\u00fchlcke K, Preu\u00dfner L, Rengstl B, T\u00fcreci \u00d6, \u015eahin U. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"1805_CR219","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2024-210017","volume":"144","author":"MR Dowling","year":"2024","unstructured":"Dowling MR, Scott HW, Connor TL, Kelly H, Lee IY, Domingues M, Manssour S, Iudica R, Kaur S, Davawala J, Dickinson C, Schobben L, Emmerson B, Rippington D, Li J, Korte J, Radhakrishnan B, Cahill T, Eland C, Blake L, Lasocki A, Frazzetto M, Hofman MS, Santamaria G, Bansal V, Hao M, Oliaro J, Wall D, Harrison SJ. CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease - an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI. Blood. 2024;144(Supplement 1):1029\u20131029.","journal-title":"Blood"},{"key":"1805_CR220","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jiec.2025.06.017","volume":"153","author":"SM Mousavi","year":"2026","unstructured":"Mousavi SM, Kalashgrani MY, Rahmanian V, Mirshafiei M, Omidifar N, Shokripour M, Lai CW, Thomas P, Aljabri MD, Rahman MM, Gholami A, Chiang W-H. Nanoparticles-Mediated CRISPR-Cas9 systems for CAR T-cell immunotherapy as smart cancer biotherapeutics. J Ind Eng Chem. 2026;153:200\u201326.","journal-title":"J Ind Eng Chem"},{"issue":"6","key":"1805_CR221","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1021\/acsbiomaterials.4c00108","volume":"10","author":"R Wang","year":"2024","unstructured":"Wang R, Huang X, Chen X, Zhang Y. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer. ACS Biomater Sci Eng. 2024;10(6):3568\u201398.","journal-title":"ACS Biomater Sci Eng"},{"issue":"1","key":"1805_CR222","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M, Frezza V, Marra E, Aurisicchio L, Roscilli G, Conforti A. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med. 2025;23(1):10.","journal-title":"J Transl Med"},{"key":"1805_CR223","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/IJN.S229858","volume":"15","author":"Q Yu","year":"2020","unstructured":"Yu Q, Zhang M, Chen Y, Chen X, Shi S, Sun K, Ye R, Zheng Y, Chen Y, Xu Y, Peng J. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification. Int J Nanomed. 2020;15:483\u201395.","journal-title":"Int J Nanomed"},{"issue":"78","key":"1805_CR224","doi-asserted-by":"publisher","first-page":"10886","DOI":"10.1039\/D2CC04826D","volume":"58","author":"A Ya\u00f1ez-Aulestia","year":"2022","unstructured":"Ya\u00f1ez-Aulestia A, Gupta NK, Hern\u00e1ndez M, Osorio-Toribio G, S\u00e1nchez-Gonz\u00e1lez E, Guzm\u00e1n-Vargas A, Rivera JL, Ibarra IA, Lima E. Gold nanoparticles: current and upcoming biomedical applications in sensing, drug, and gene delivery. Chem Commun (Camb). 2022;58(78):10886\u201395.","journal-title":"Chem Commun (Camb)"},{"issue":"33","key":"1805_CR225","doi-asserted-by":"publisher","first-page":"18707","DOI":"10.1021\/acsami.5b05228","volume":"7","author":"L Song","year":"2015","unstructured":"Song L, Guo Y, Roebuck D, Chen C, Yang M, Yang Z, Sreedharan S, Glover C, Thomas JA, Liu D, Guo S, Chen R, Zhou D. Terminal PEGylated DNA-Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of DNA Binding Agents. ACS Appl Mater Interfaces. 2015;7(33):18707\u201316.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1805_CR226","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1021\/nn800702n","volume":"3","author":"A Wijaya","year":"2009","unstructured":"Wijaya A, Schaffer SB, Pallares IG, Hamad-Schifferli K. Selective release of multiple DNA oligonucleotides from gold nanorods. ACS Nano. 2009;3(1):80\u20136.","journal-title":"ACS Nano"},{"key":"1805_CR227","doi-asserted-by":"crossref","unstructured":"Kim M, Hwang Y, Lim S, Jang H-K, Kim H-O. Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR\/Cas9. Pharmaceutics. 2024;16(9):1197.","DOI":"10.3390\/pharmaceutics16091197"},{"issue":"1","key":"1805_CR228","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/toxsci\/kfj122","volume":"91","author":"JP Ryman-Rasmussen","year":"2006","unstructured":"Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci. 2006;91(1):159\u201365.","journal-title":"Toxicol Sci"},{"issue":"7","key":"1805_CR229","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1080\/00498254.2016.1205762","volume":"47","author":"D Nath Roy","year":"2017","unstructured":"Nath Roy D, Goswami R, Pal A. Nanomaterial and toxicity: what can proteomics tell us about the nanotoxicology? Xenobiotica. 2017;47(7):632\u201343.","journal-title":"Xenobiotica"},{"key":"1805_CR230","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"issue":"7","key":"1805_CR231","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","volume":"12","author":"X Shan","year":"2022","unstructured":"Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028\u201348.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"1805_CR232","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","volume":"13","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023;13(11):4391\u2013416.","journal-title":"Acta Pharm Sin B"},{"key":"1805_CR233","doi-asserted-by":"publisher","first-page":"1635159","DOI":"10.3389\/fimmu.2025.1635159","volume":"16","author":"JC Baena","year":"2025","unstructured":"Baena JC, Victoria JS, Toro-Pedroza A, Arag\u00f3n CC, Ortiz-Guzman J, Garcia-Robledo JE, Torres D, Rios-Serna LJ, Albornoz L, Rosales JD, Ca\u00f1as CA, Cruz-Suarez A, Osorio G, Fleitas FO, Laponogov T, Loukanov I, Veselkov A. Smart CAR-T Nanosymbionts: archetypes and proto-models. Front Immunol. 2025;16:1635159.","journal-title":"Front Immunol"},{"key":"1805_CR234","doi-asserted-by":"publisher","first-page":"157454","DOI":"10.1016\/j.cej.2024.157454","volume":"500","author":"A Mottafegh","year":"2024","unstructured":"Mottafegh A, Joo J-U, Na G-S, Sharma V, Kim D-P. AI-assisted autonomous manufacturing of tailored drug-loaded nanoparticles by multi-step continuous-flow platform. Chem Eng J. 2024;500:157454.","journal-title":"Chem Eng J"},{"issue":"18","key":"1805_CR235","doi-asserted-by":"publisher","first-page":"e2211509","DOI":"10.1002\/adma.202211509","volume":"35","author":"X Tang","year":"2023","unstructured":"Tang X, Yang Y, Zheng M, Yin T, Huang G, Lai Z, Zhang B, Chen Z, Xu T, Ma T, Pan H, Cai L. Magnetic-Acoustic Sequentially Actuated CAR T Cell Microrobots for Precision Navigation and In Situ Antitumor Immunoactivation. Adv Mater. 2023;35(18):e2211509.","journal-title":"Adv Mater"},{"key":"1805_CR236","doi-asserted-by":"crossref","unstructured":"Pfister F, Carnell LR, L\u00f6ffler L, Boosz P, Schaft N, D\u00f6rrie J, Stein R, Lenz M, Spiecker E, Huber CM, Haddadin S, Berking C, Alexiou C, Janko C. Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism. MedComm (2020). 2025;6(1):e70039.","DOI":"10.1002\/mco2.70039"},{"issue":"6625","key":"1805_CR237","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, Wang S, Simic MS, Bhargava HK, Capponi S, Tonai Y, Yu W, Bianco S, Lim WA. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;378(6625):1194\u2013200.","journal-title":"Science"},{"key":"1805_CR238","doi-asserted-by":"publisher","first-page":"104367","DOI":"10.1016\/j.jbi.2023.104367","volume":"142","author":"A Bogatu","year":"2023","unstructured":"Bogatu A, Wysocka M, Wysocki O, Butterworth H, Pillai M, Allison J, Landers D, Kilgour E, Thistlethwaite F, Freitas A. Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy. J Biomed Inf. 2023;142:104367.","journal-title":"J Biomed Inf"},{"issue":"4","key":"1805_CR239","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","volume":"11","author":"B Bhinder","year":"2021","unstructured":"Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov. 2021;11(4):900\u201315.","journal-title":"Cancer Discov"},{"issue":"48","key":"1805_CR240","doi-asserted-by":"publisher","first-page":"47893","DOI":"10.1021\/acsomega.4c09718","volume":"9","author":"H Feng","year":"2024","unstructured":"Feng H, Sun X, Li N, Xu Q, Li Q, Zhang S, Xing G, Zhang G, Wang F. Machine Learning-Driven Methods for Nanobody Affinity Prediction. ACS Omega. 2024;9(48):47893\u2013902.","journal-title":"ACS Omega"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01805-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:02:33Z","timestamp":1782403353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01805-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":240,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01805-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}